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Clinical predictors of prophylaxis use prior to the onset of acute
venous thromboembolism in hospitalized patients SWIss Venous
ThromboEmbolism Registry (SWIVTER)
Abstract
BACKGROUND: We investigated clinical predictors of appropriate prophylaxis prior to the onset of
venous thromboembolism (VTE). METHODS: In 14 Swiss hospitals, 567 consecutive patients (306
medical, 261 surgical) with acute VTE and hospitalization < 30 days prior to the VTE event were
enrolled. RESULTS: Prophylaxis was used in 329 (58%) patients within 30 days prior to the VTE event.
Among the medical patients, 146 (48%) received prophylaxis, and among the surgical patients, 183
(70%) received prophylaxis (P < 0.001). The indication for prophylaxis was present in 262 (86%)
medical patients and in 217 (83%) surgical patients. Among the patients with an indication for
prophylaxis, 135 (52%) of the medical patients and 165 (76%) of the surgical patients received
prophylaxis (P < 0.001). Admission to the intensive care unit [odds ratio (OR) 3.28, 95% confidence
interval (CI) 1.94-5.57], recent surgery (OR 2.28, 95% CI 1.51-3.44), bed rest > 3 days (OR 2.12, 95%
CI 1.45-3.09), obesity (OR 2.01, 95% CI 1.03-3.90), prior deep vein thrombosis (OR 1.71, 95% CI
1.31-2.24) and prior pulmonary embolism (OR 1.54, 95% CI 1.05-2.26) were independent predictors of
prophylaxis. In contrast, cancer (OR 1.06, 95% CI 0.89-1.25), age (OR 0.99, 95% CI 0.98-1.01), acute
heart failure (OR 1.13, 95% CI 0.79-1.63) and acute respiratory failure (OR 1.19, 95% CI 0.89-1.59)
were not predictive of prophylaxis. CONCLUSIONS: Although an indication for prophylaxis was
present in most patients who suffered acute VTE, almost half did not receive any form of prophylaxis.
Future efforts should focus on the improvement of prophylaxis for hospitalized patients, particularly in
patients with cancer, acute heart or respiratory failure, and in the elderly.
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Background:  We investigated clinical predictors of appropriate prophylaxis prior to the onset of 
venous thromboembolism (VTE).  
Methods: In 14 Swiss hospitals, 567 consecutive patients (306 medical, 261 surgical) with acute 
VTE and hospitalization  <30 days prior to the VTE event were enrolled.  
Results:  Prophylaxis was used in 329 (58%) patients within 30 days prior to the VTE event. 
Among the medical patients, 146 (48%) received prophylaxis, and among the surgical patients, 
183 (70%) received prophylaxis (p <0.001). The indication for prophylaxis was present in 262 
(86%) medical patients and in 217 (83%) surgical patients. Among the patients with an indication 
for prophylaxis, 135 (52%) of the medical patients and 165 (76%) of the surgical patients 
received prophylaxis (p <0.001). Admission to the intensive care unit (OR 3.28, 95%CI 1.94-
5.57), recent surgery (OR 2.28, 95%CI 1.51-3.44), bed rest >3 days (OR 2.12, 95%CI 1.45-3.09), 
obesity (OR 2.01, 95%CI 1.03-3.90), prior DVT (OR 1.71, 95%CI 1.31-2.24), and prior PE (OR 
1.54, 95%CI 1.05-2.26) were independent predictors of prophylaxis. In contrast, cancer (OR 
1.06, 95%CI 0.89-1.25), age (OR 0.99, 95%CI 0.98-1.01), acute heart failure (OR 1.13, 95%CI 
0.79-1.63), and acute respiratory failure (OR 1.19, 95%CI 0.89-1.59) were not predictive of 
prophylaxis. 
Conclusions: Although an indication for prophylaxis was present in most patients who suffered 
acute VTE, almost half did not receive any form of prophylaxis. Future effort should focus on the 
improvement of prophylaxis in hospitalized patients, particularly in patients with cancer, acute 
heart or respiratory failure, and in the elderly. 
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Venous thromboembolism (VTE) encompasses deep vein thrombosis and pulmonary embolism 
(PE). VTE remains a major health problem in the European countries, with over one million VTE 
events or deaths per annum, and almost three-quarters of all VTE-related deaths are the result of 
hospital-acquired VTE (1). VTE among hospitalized patients occurs frequently, with recent 
surgery or trauma, cancer, advanced age, a personal history of VTE, acute cardiac or respiratory 
failure as most important risk factors (2, 3). PE is a potentially fatal disease with a 3-month 
mortality rate as high as 17%, with right ventricular failure as the most common cause of death 
(4, 5). In addition, at least one third of the patients with DVT suffer debilitating postthrombotic 
syndrome (6).  
Randomized controlled trials confirmed that thromboprophylaxis among high-risk patients safely 
prevents VTE, with a more than 75% reduction in relative risk of VTE compared to placebo (7, 
8). However, several observational studies from various countries have confirmed that 
prophylaxis among hospitalized patients at risk continues to be underused (1, 9-14). 
We explored the use of appropriate mechanical or pharmacological prophylaxis among medical 
and surgical patients who suffered acute VTE during or shortly after a hospitalization. For a 
better understanding of practice patterns, we also investigated patient factors that affected the use 




Four academic and 10 non-academic primary-tertiary care hospitals in Switzerland participated in 
the prospective SWIss Venous ThromboEmbolism Registry (SWIVTER) and enrolled 
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consecutive patients with objectively confirmed acute DVT or PE between April 1, 2006 and 
March 31, 2008. DVT had to be confirmed with ultrasound or phlebography, and PE had to be 
confirmed by contrast-enhanced chest computed tomography, ventilation perfusion scan, 
conventional pulmonary angiography, or magnetic resonance imaging.  
Medical or surgical patients were included if they were at least 18 years old and if they were 
hospitalized for an acute illness other than VTE within 30 days prior to the onset of acute VTE 
(medical patients) or if they were hospitalized with trauma or surgery within 30 days prior to the 
onset of acute VTE (surgical patients). There were no exclusion criteria. The study was approved 
by the Independent Review Board Zurich, Switzerland. 
 
Data collection and Statistical analysis 
Data on patient demographics, acute and chronic comorbidities, VTE risk factors, type and 
duration of thromboprophylaxis prior to the VTE event, and 7-day mortality were collected. Data 
were entered by site investigator physicians from the patient chart directly into a password-
protected and secured web-based electronic case report form. Data extraction and data base entry 
was performed by an independent data coordinating center (la volta statistics, Zurich, 
Switzerland).  
Patients were classified as inpatients if they were hospitalized for any other diagnosis than VTE 
but developed VTE during the same hospitalization as a complication. Patients were classified as 
outpatients if they were diagnosed with VTE as outpatients but had a recent hospitalization for 
any other diagnosis than VTE within 30 days of the VTE event.  
For the assessment of the indication for prophylaxis in surgical patients, we used the 
recommendations from the American College of Chest Physicians (ACCP) 2004 (15). Briefly, 
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prophylaxis is indicated in patients undergoing major orthopedic surgery, cancer surgery, and 
neurosurgery, even without the presence of additional VTE risk factors. At least one additional 
VTE risk factor is required for routine prophylaxis in patients undergoing abdominal surgery, 
thoracic surgery, reconstructive surgery, breast surgery, cardiac surgery, vascular surgery, 
arthroscopy, or in patients with major trauma. Multiple VTE risk factors are required for 
prophylaxis in patients undergoing genitourinary surgery.  
For the assessment of the indication of prophylaxis in medical patients, we used the Geneva VTE 
prophylaxis risk score that allows an objective risk assessment for identifying high-risk medical 
patients (16). According to this score, prophylaxis is indicated in all patients with a score >3 
points. Two score points are allocated to the following risk factors: cardiac failure, respiratory 
failure, recent stroke, recent myocardial infarction, acute infectious disease (including sepsis), 
acute rheumatic disease, cancer, myeloproliferative syndrome, nephrotic syndrome, prior VTE, 
and known hypercoagulable state; 1 score point is allocated to the following risk factors: 
immobilization > 3 days, recent travel > 6 hours, age > 60 years, body mass index > 30 kg/m2, 
chronic venous insufficiency, pregnancy, hormonal therapy, and dehydration. 
Continuous variables with a normal distribution are described as means with standard deviations 
and group comparisons were performed with the t-test; continuous variables with skewed 
distribution are presented as median values with interquartile ranges and group comparisons were 
performed with a ranksum test. Discrete variables are presented as frequencies and percentages 
and group comparisons were performed using the chi square or Fisher’s exact test. Bonferroni’s 
correction for multiple group comparisons indicated a p-value of less than 0.002 for statistical 
significance. Univariate logistic regression analysis reporting Odds ratios with 95% confidence 
intervals was conducted to identify clinical predictors for the use of prophylaxis within 30 days 
prior to the onset of VTE. Then, multivariate logistic regression analysis was performed to 
  6 
 
 6 
identify independent clinical predictors of prophylaxis within 30 days prior to the onset of VTE. 
Univariate predictors with a p-value <0.05 were included in the regression model; a backward 
elimination procedure was used to discard variables without significance stepwise from the 
model. All reported p-values are two tailed. Data were analyzed using STATA 9 software 
(STATACorp LP, College Station, Texas, USA). 
 
Funding of study 
The study was funded by an unrestricted educational grant from sanofi-aventis (suisse) sa, 




Overall, 567 patients with a mean age of 62 ± 16 years (51% men) were enrolled. Men were 
younger than women (Figure 1). In 4 academic centers, 408 (72%) patients, and in 10 non-
academic centers, 159 (28%) patients were enrolled; 306 (54%) were medical patients and 261 
(46%) were surgical patients. At the time of VTE diagnosis, 379 (67%) were inpatients and 188 
(33%) were outpatients with a hospitalization within 30 days prior to the VTE event. DVT alone 
was diagnosed in 222 (39%), acute PE in 218 (38%), and PE plus DVT in 127 (22%) patients. 
Overall, 34 (6.0%) patients died within 7 days post VTE diagnosis. VTE was the main cause of 
death in 19 (56%) of these patients, and VTE likely contributed to death in 26 (77%).  
The most common chronic comorbidities were cancer (45%), arterial hypertension (35%), prior 
DVT (18%), neurological disorder (15%), and chronic lung disease (15%) (Table 1). Overall, 318 
(56%) of the patients were immobilized with bed rest of more than 3 days. The most common 
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acute comorbidities were non-pulmonary infection (24%), active cancer with ongoing 
chemotherapy (20%), bleeding (16%), and pulmonary infection (13%). Among the 91 patients 
with a bleeding complication, 31 (34%) received transfusions and 33 (36%) underwent surgery to 
control the bleeding. In total, 261 (46%) had surgery or major trauma within 30 days before VTE 
diagnosis; the most common surgery types were neurosurgery (26%), abdominal surgery (23%), 
and orthopedic or trauma surgery (20%). Overall, 138 (24%) patients were admitted to the 
intensive care unit (ICU). The median hospital length of stay was 15 days (interquartile range 8 – 
26 days).  
 
Type and duration of VTE prophylaxis within 30 days prior to the onset of VTE 
Thromboprophylaxis was used in 329 (58%) patients. Mechanical prophylaxis was used in 98 
(17%); 93 (16%) received graduated compression stockings and 5 (1%) intermittent pneumatic 
compression devices. Vena cava filters were implanted in 6 (1%) patients. Pharmacological 
prophylaxis was administered in 281 (50%) patients, of whom 55 (20%) received a therapeutic 
dose regimen. Among the patients with pharmacological prophylaxis, 202 (72%) received low-
molecular weight heparins (LMWH) with a median length of treatment of 9 days (interquartile 
range 5 – 15 days). The median dose in patients with LMWH prophylaxis was equal to 
recommended prophylactic dose regimens (Table 2). Unfractionated heparin (UFH) was used in 
53 (19%) patients with a median length of treatment of 8 days (interquartile range 3 – 20 days); 
39 (14%) patients were receiving vitamin K antagonists prior to the onset of VTE. Combined 
mechanical and pharmacological prophylaxis was used in 50 (9%) patients.  
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VTE prophylaxis in medical and surgical patients 
Among the medical patients, 146 (48%) received prophylaxis, and among surgical patients, 183 
(70%) received prophylaxis (p <0.001). The indication for prophylaxis was present in 262 (86%) 
medical patients and in 217 (83%) surgical patients. Among the patients with an indication for 
prophylaxis, 135 (52%) of the medical patients and 165 (76%) of the surgical patients received 
prophylaxis (p <0.001). Prophylaxis within 30 days was more frequently used in inpatients (n = 
243; 65%) than in outpatients (n = 86; 46%) (p <0.001), regardless of the VTE presentation 
(Figure 2). 
 
Predictors of VTE prophylaxis 
The strongest univariate predictors for the use of thromboprophylaxis within 30 days prior to the 
onset of VTE were admission to the intensive care unit, use of an indwelling central catheter, 
surgery, and bed rest >3 days (Table 3). None of the other patient factors listed in Table 1 were 
predictive for the use of prophylaxis, particularly not cancer (OR 1.06, 95% CI 0.89-1.25), age 
(OR 0.99, 95% CI 0.98-1.01), acute heart failure (OR 1.13, 95% CI 0.79-1.63), or acute 
respiratory failure (OR 1.19, 95% CI 0.89-1.59).  
The final multivariate logistic model identified the following independent predictors for the use 
of thromboprophylaxis within 30 days prior to the onset of VTE: admission to the intensive care 
unit, surgery, bed rest >3 days, obesity, and personal history of DVT or PE (Table 4). 
 
Discussion 
The Swiss Venous Thromboembolism Registry showed that only 58% of the patients who 
developed acute VTE during or shortly after hospitalization were receiving thromboprophylaxis. 
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This finding confirms the results of previous observational studies that many hospitalized patients 
do not receive prophylaxis prior to the onset of acute VTE. The rate of prophylaxis among 
patients with development of VTE during hospitalization was higher in SWIVTER (65%) than in 
the U.S. American DVTFREE registry, of whom only 42% of the inpatients were receiving 
prophylaxis prior to the onset of VTE (10). In the Spanish RIETE registry, only 28% medical and 
67% surgical patients received VTE prophylaxis prior to in-hospital development of VTE (11).  
In comparison to VTE inpatients, the underuse of prophylaxis is similar in VTE outpatients with 
recent hospitalization. An observational study from the Worcester metropolitan area showed that 
approximately half of the patients with acute VTE diagnosed in the outpatient setting had a recent 
hospitalization within 3 months, and that only 43% of these patients received prophylaxis during 
that hospitalization (17). In our registry, the rate of prophylaxis among outpatients with 
hospitalization within 30 days prior to the onset of VTE was similarly low (46%).  
SWIVTER enrolled high-risk patients, including the elderly, and the most important VTE risk 
factors, including cancer, prior VTE, neurological disorder, chronic lung disease, infections, and 
recent surgery, were frequent.  Therefore, most (>80%) of the patients had an indication for 
prophylaxis according to current recommendations.  Hemorrhage prior to the onset of VTE was 
also common (16%) and may in part explain the omission of pharmacological 
thromboprophylaxis in some patients. The rate of prophylaxis in men and women was similar in 
SWIVTER (Table 1), and we could not confirm the finding from the U.S. American DVTFREE 
registry that women were less likely than men to receive prophylaxis prior to the onset of VTE 
(18). 
The use of mechanical prophylaxis (16%) in SWIVTER was infrequent as was the use of 
combined mechanical and pharmacological prophylaxis (9%). Graduated compressions stockings 
should be considered particularly if contraindications to pharmacological prophylaxis are present. 
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In contrast to the U.S. American DVTFREE registry (10), vena cava filters and intermittent 
pneumatic compression devices were rarely used in the present survey (both at a rate of 1%). 
In SWIVTER, we searched for patient factors that could explain the low rate of prophylaxis. It 
was demonstrated that several important VTE risk factors, including admission to the intensive 
care unit, surgery, bed rest >3 days, obesity, and personal history of VTE were associated with 
prophylaxis administration and independently predicted the use of prophylaxis. We were 
surprised by the finding that other important risk factors, such as cancer, advanced age, acute 
heart failure, or acute respiratory failure were not predictive for the use of prophylaxis. Future 
quality improvement initiatives, including electronic or human alerts (19), continuing medical 
education (20), regional and practice-specific guidelines, or individual hospital protocols, should 
focus on improving prophylaxis, especially in these high-risk patients. 
Strengths of the present survey include the prospective enrollment of consecutive patients, who 
suffered VTE during or shortly after hospitalization, and the collection of detailed information on 
comorbidities and VTE risk factors as well as prophylaxis modalities. A weakness of the registry 
is that information on other factors that may affect the use prophylaxis, including compliance of 
health care professionals as well as institutional factors, was not collected. For example, some of 
the participating institutions had started quality improvement initiatives for thromboprophylaxis 
during the study period.  
In conclusion, almost half of the patients who suffered acute VTE as a complication during or 
shortly after a hospitalization did not receive any form of prophylaxis within 30 days prior to the 
event, although most enrolled patients had an indication for prophylaxis. Some well-established 
risk factors, including cancer, age, acute heart or respiratory failure were not predictive for the 
use of VTE prophylaxis, and future effort should focus on the improvement of prophylaxis in 
these patients. 
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Table 1. Patient characteristics  
  Total 
N = 567 
Prophylaxis 
N = 329 
No Prophylaxis 
N = 238 
p 
Age, years 62 ± 16 61.7 ± 16.4 62.9 ± 16.0 0.20 
Male, n (%) 291 (51.3) 165 (56.7) 126 (43.3)  
Women, n (%) 276 (48.7) 164 (59.4) 112 (40.6) 0.51 
Chronic comorbidities      
Cancer, n (%) 257 (45.3) 153 (46.5) 104 (43.7) 0.51 
Hypertension, n (%) 200 (35.3) 112 (34.0) 88 (37.0) 0.47 
Prior DVT, n (%) 101 (17.8) 73 (22.2) 28 (11.8) 0.001 
Neurologic disorder, n (%) 87 (15.3) 48 (14.6) 39 (16.4) 0.56 
Chronic lung disease, n (%) 85 (15.0) 47 (14.3) 38 (16.0) 0.58 
Coronary artery disease, n (%) 76 (13.4) 42 (12.8) 34 (14.3) 0.60 
Congestive heart failure, n (%) 59 (10.4) 33 (10.0) 26 (10.9) 0.73 
Obesity, n (%) 57 (10.1) 42 (12.8) 15 (6.3) 0.012 
Prior PE, n (%) 47 (8.3) 35 (10.6) 12 (5.0) 0.017 
Renal failure, n (%) 40 (7.0) 24 (7.3) 16 (6.7) 0.79 
Varicous veins, n (%) 39 (6.9) 25 (7.6) 14 (5.9) 0.42 
Known thrombophilia, n (%) 10 (5.7) 8 (2.4) 2 (0.8) 0.16 
Pregnancy, n (%) 6 (1.1) 5 (1.5) 1 (0.4) 0.21 
     
Acute comorbidities < 30 days     
Bed rest >3 days, n (%) 318 (56.1) 212 (64.4) 106 (44.5) <0.001 
Surgery, n (%)* 239 (42.2) 174 (52.9) 65 (27.3) <0.001 
Indwelling central line, n (%) 140 (24.7) 108 (32.8) 32 (13.4) <0.001 
ICU admission, n (%) 138 (24.3) 113 (34.4) 25 (10.5) <0.001 
Non-pulmonary infection, n (%) 134 (23.6) 70 (21.3) 54 (22.7) 0.69 
Ongoing chemotherapy, n (%) 115 (20.3) 59 (17.9) 56 (23.5) 0.10 
Bleeding, n (%) 91 (16.0) 49 (14.9) 42 (13.4) 0.63 
Pulmonary infection, n (%) 72 (12.7) 39 (11.8) 33 (13.9) 0.48 
Trauma, n (%) 60 (10.6) 40 (12.2) 20 (8.4) 0.15 
Acute respiratory failure, n (%) 55 (9.7) 36 (10.9) 19 (8.0) 0.24 
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Ischemic stroke or palsy, n (%) 51 (9.0) 40 (12.2) 11 (4.6) 0.002 
Acute rheumatic disease, n (%) 42 (7.4) 17 (5.2) 25 (10.5) 0.017 
Sepsis, n (%) 39 (6.9) 27 (8.2) 12 (5.0) 0.14 
Acute heart failure, n (%) 33 (5.8) 21 (6.4) 12 (5.0) 0.50 
Acute coronary syndrome, n (%) 17 (3.0) 10 (3.0) 7 (2.9) 0.95 
* some patients had more than 1 surgical procedure. 
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 Table 2. Pharmacological modalities among patients with VTE prophylaxis (N=281) 
















14.0 ± 35.0 8 
(5-14) 




13.6 ± 14.7 8 
(3-20) 
Enoxaparin 39 (13.9) 38 (97.4) 38 ± 8 mg 40 mg 
(20, 60) 
14.2 ± 30.8 7 
(3-12) 




13.7 ± 15.6 12 
(7-15) 
Coumadin 39 (13.9) 9 (23.1) - - - - 
Fondaparinux 1 (0.4) 1 (100) 2.5 mg 2.5 mg 11 11 
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Table 3. Univariate Clinical Predictors for Receiving Prophylaxis Prior to the Onset of VTE 
 
Predictor OR 95% CI p 
ICU admission 4.46 2.78-7.15 <0.001 
Indwelling central line 3.15 2.03-4.87 <0.001 
Surgery within 30 days 2.99 2.09-4.23 <0.001 
Bed rest >3 days 2.26 1.60-3.17 <0.001 
Obesity 2.18 1.18-4.02 0.013 
Hospital days >15 (median) 1.74 1.24-2.44 0.001 
Ischemic stroke or palsy within 30 days 1.69 1.20-2.39 0.003 
Prior PE 1.50 1.07-2.10 0.020 
Prior DVT 1.46 1.15-1.85 0.002 
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Table 4. Independent Clinical Predictors for Receiving Prophylaxis Prior to the Onset of 
VTE 
 
Predictor OR 95% CI p 
ICU admission 3.28 1.94-5.57 <0.001 
Surgery within 30 days 2.28 1.51-3.44 <0.001 
Bed rest > 3 days 2.12 1.45-3.09 <0.001 
Obesity 2.01 1.03-3.90 0.040 
Prior DVT 1.71 1.31-2.24 <0.001 
Prior PE 1.54 1.05-2.26 0.027 
 




Figure 1. Distribution of patients by age and gender 




Figure 2. Prophylaxis use prior to VTE event according to patient status and VTE 
presentation 
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